Medical devices maker Boston Scientific Corp. (BSX) Wednesday, announced that the U.S. District Court for the District of Delaware has found all four patents in a suit involving Johnson & Johnson (JNJ) to be invalid.
As part of a 2007 suit, Johnson & Johnson had alleged that Boston Scientific's PROMUS Everolimus-Eluting Coronary Stent System infringed these four patents, known as the Wright/Falotico patents. The patents relate to coatings, drug and polymer, for drug-eluting stents.
The court ruled that a trial on the four patents, which was scheduled to begin February 9, will not proceed.
Ray Elliott, President and Chief Executive Officer of Boston Scientific said, "We are pleased with the court's finding that all four Johnson & Johnson patents are invalid. Boston Scientific will continue to vigorously defend against any charges of infringement. We continue to attempt to resolve remaining outstanding matters with Johnson & Johnson."
BSX closed Wednesday's regular trading at $9.48 down $0.14 or 1.46% on a volume of 33.138 million shares on the NYSE. In the after hour trading the stock value further decreased to $9.40 down $0.08 or 0.84%.
JNJ closed Wednesday's regular trading at $65.15 down $0.20 or 0.31% on a volume of 13.025 million shares on the NYSE.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.